Milodistim
| Milodistim | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Milodistim is a recombinant protein that acts as a cytokine to stimulate the production of blood cells in the bone marrow. It is primarily used in the context of hematopoietic stem cell transplantation and chemotherapy to enhance the recovery of the immune system.
Mechanism of Action[edit]
Milodistim functions as a multi-lineage cytokine, meaning it can stimulate the production of multiple types of blood cells, including neutrophils, erythrocytes, and platelets. It acts by binding to specific receptors on the surface of hematopoietic stem cells, triggering a cascade of intracellular signals that promote cell proliferation and differentiation.
Clinical Applications[edit]
Milodistim is used in patients undergoing chemotherapy or bone marrow transplantation to accelerate the recovery of the hematopoietic system. By stimulating the production of white blood cells, it helps reduce the risk of infection in immunocompromised patients. Additionally, it can be used to treat certain types of anemia by promoting the production of red blood cells.
Side Effects[edit]
Common side effects of Milodistim include bone pain, fever, and fatigue. More serious side effects can include allergic reactions, splenomegaly, and thrombocytopenia. Patients receiving Milodistim should be monitored for these adverse effects, and dosage adjustments may be necessary.
Research and Development[edit]
Milodistim is currently under investigation in various clinical trials to assess its efficacy in different therapeutic contexts. Research is ongoing to optimize its use in combination with other growth factors and chemotherapeutic agents.
Regulatory Status[edit]
As of the latest update, Milodistim is approved for use in several countries for specific indications related to hematopoietic recovery. Its approval status may vary by region, and ongoing studies may expand its indications.
Also see[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
